AzaCITIDine

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11238 publications

Efficacy and safety of ivosidenib-based therapy in 16 patients with IDH1-mutated acute myeloid leukemia

Efficacy and safety of ivosidenib-based therapy in 16 patients with IDH1-mutated acute myeloid leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: September 07, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia.

Journal: International journal of clinical oncology

Published: September 06, 2026

Synergistic epigenetic modulation and ferroptosis induction via codelivery of Decitabine and Sorafenib for potent anti-tumor therapy.

Synergistic epigenetic modulation and ferroptosis induction via codelivery of Decitabine and Sorafenib for potent anti-tumor therapy.

Journal: Drug delivery

Published: September 03, 2026

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Journal: The New England journal of medicine

Published: September 02, 2026

Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm

Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 30, 2026

Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS

Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 30, 2026

Health-system burden of higher-risk myelodysplastic syndromes in England: a literature-based micro-cost analysis.

Health-system burden of higher-risk myelodysplastic syndromes in England: a literature-based micro-cost analysis.

Journal: BMJ open

Published: August 28, 2026

STING agonists in combination with epigenetic drugs potentiate ZNFX1-driven inflammatory necroptosis in TP53 -mutated AML.

STING agonists in combination with epigenetic drugs potentiate ZNFX1-driven inflammatory necroptosis in TP53 -mutated AML.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2026

Integrated Patient-Derived Xenograft and Patient-Derived Cell Models Reveal Therapeutic Vulnerabilities Beyond Standard-of-Care Therapy in Endometrial Cancer.

Integrated Patient-Derived Xenograft and Patient-Derived Cell Models Reveal Therapeutic Vulnerabilities Beyond Standard-of-Care Therapy in Endometrial Cancer.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2026

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.

Journal: Science translational medicine

Published: August 12, 2026

Correction: Decitabine attenuates ischemic stroke by reducing astrocytes proliferation in rats.

Correction: Decitabine attenuates ischemic stroke by reducing astrocytes proliferation in rats.

Journal: PloS one

Published: August 10, 2026

Epigenetic Modulation of Thyroid-Stimulating Hormone Receptor Expression in Orbital Fibroblasts From Graves' Ophthalmopathy: Target for Treatment.

Epigenetic Modulation of Thyroid-Stimulating Hormone Receptor Expression in Orbital Fibroblasts From Graves' Ophthalmopathy: Target for Treatment.

Journal: Investigative ophthalmology & visual science

Published: August 07, 2026

Showing 1-12 of 11,238

Last Updated: 09/26/2026